Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of PF-07081532 vs Rybelsus in type 2 diabetes mellitus with obesity
2022-002834-15Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lotiglipron in type 2 diabetes mellitus (T2DM) and obesity (7 arms), sponsored by Pfizer. Primary endpoint: Placebo-adjusted change from baseline in HbA1c at Week 32. Started Oct 2022; status: terminated.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on 2022-002834-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002834-15.